big pharma, page-6

My opinion/feeling is that initially there would have been some interest when the moved onto Ph II.

Then it may have died off and the big pharma will be letting them wear the path, given that immunotherapy is relatively new and unproven I.e. high risk as there isn't amazing first mover advantage in the overall field just specific applications. So they will be focusing on what they have and as the field is better understood they will NOW be willing to take out juniors for decent money.

While all along they are likely to be in touch and high level discussions with Prima, waiting to strike when positive Ph II/III results come in.

Things are going to get exciting so hold on for the ride!